180 related articles for article (PubMed ID: 9434467)
1. [Combination therapy of insulin sensitizer and sulfonylurea].
Hari J
Nihon Rinsho; 1997 Nov; 55 Suppl():197-203. PubMed ID: 9434467
[No Abstract] [Full Text] [Related]
2. [Combination therapy of insulin sensitizer, thiazolidinedione drugs, and sulfonylurea].
Ohmura E; Hosaka D; Imai Y; Kawazu S
Nihon Rinsho; 2002 Sep; 60 Suppl 9():470-5. PubMed ID: 12387036
[No Abstract] [Full Text] [Related]
3. The effect of a thiazolidinedione drug, troglitazone, on glycemia in patients with type 2 diabetes mellitus poorly controlled with sulfonylurea and metformin. A multicenter, randomized, double-blind, placebo-controlled trial.
Yale JF; Valiquett TR; Ghazzi MN; Owens-Grillo JK; Whitcomb RW; Foyt HL
Ann Intern Med; 2001 May; 134(9 Pt 1):737-45. PubMed ID: 11329231
[TBL] [Abstract][Full Text] [Related]
4. Troglitazone in combination with sulfonylurea restores glycemic control in patients with type 2 diabetes. The Troglitazone Study Group.
Horton ES; Whitehouse F; Ghazzi MN; Venable TC; Whitcomb RW
Diabetes Care; 1998 Sep; 21(9):1462-9. PubMed ID: 9727892
[TBL] [Abstract][Full Text] [Related]
5. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study.
Kipnes MS; Krosnick A; Rendell MS; Egan JW; Mathisen AL; Schneider RL
Am J Med; 2001 Jul; 111(1):10-7. PubMed ID: 11448655
[TBL] [Abstract][Full Text] [Related]
6. Troglitazone or metformin in combination with sulfonylureas for patients with type 2 diabetes?
Kirk JK; Pearce KA; Michielutte R; Summerson JH
J Fam Pract; 1999 Nov; 48(11):879-82. PubMed ID: 10907625
[TBL] [Abstract][Full Text] [Related]
7. Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Troglitazone Study Group.
Kumar S; Boulton AJ; Beck-Nielsen H; Berthezene F; Muggeo M; Persson B; Spinas GA; Donoghue S; Lettis S; Stewart-Long P
Diabetologia; 1996 Jun; 39(6):701-9. PubMed ID: 8781766
[TBL] [Abstract][Full Text] [Related]
8. Effects of troglitazone in patients with type 2 diabetes mellitus not adequately controlled by sulfonylureas.
Bunnag P; Puavilai G; Chanprasertyotin S; Chandraprasert S; Suwanwalaikorn S; Suthijumroon A; Benjasuratwong Y; Boonyavarakul A; Nitiyanant W; Sriussadaporn S; Deerochanawong C;
Diabetes Res Clin Pract; 2001 Feb; 51(2):151-3. PubMed ID: 11253769
[No Abstract] [Full Text] [Related]
9. A treatment for Mr WP: thiazolidinediones after troglitazone.
Montague CT
Diabet Med; 2002; 19 Suppl 1():7-9. PubMed ID: 11871423
[No Abstract] [Full Text] [Related]
10. [Combination therapy with sulfonylurea and alpha-glucosidase inhibitor].
Iijima T
Nihon Rinsho; 1997 Nov; 55 Suppl():186-91. PubMed ID: 9434465
[No Abstract] [Full Text] [Related]
11. Troglitazone monotherapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled study. The Troglitazone Study Group.
Fonseca VA; Valiquett TR; Huang SM; Ghazzi MN; Whitcomb RW
J Clin Endocrinol Metab; 1998 Sep; 83(9):3169-76. PubMed ID: 9745421
[TBL] [Abstract][Full Text] [Related]
12. Primary, secondary, tertiary, and quaternary treatment with troglitazone in type 2 diabetes mellitus in an outpatient clinical practice.
Hershon KS; Hershon PM
Endocr Pract; 2000; 6(1):20-5. PubMed ID: 11419922
[TBL] [Abstract][Full Text] [Related]
13. Beneficial effect of troglitazone, an insulin-sensitizing antidiabetic agent, on coronary circulation in patients with non-insulin-dependent diabetes mellitus.
Sekiya M; Suzuki J; Watanabe K; Funada J; Otani T; Akutsu H
Jpn Circ J; 2001 Jun; 65(6):487-90. PubMed ID: 11407727
[TBL] [Abstract][Full Text] [Related]
14. Establishing the dose response curve for metabolic control with troglitazone, an insulin action enhancer, in type 2 diabetes patients.
Young MA; Eckland DJ; Eastmond R; Lettis S
Ann Med; 1998 Apr; 30(2):206-12. PubMed ID: 9667800
[TBL] [Abstract][Full Text] [Related]
15. Troglitazone combination therapy in obese type 2 diabetic patients poorly controlled with alpha-glucosidase inhibitors.
Bando Y; Ushiogi Y; Okafuji K; Toya D; Tanaka N; Fujisawa M
J Int Med Res; 1999; 27(2):53-64. PubMed ID: 10446691
[TBL] [Abstract][Full Text] [Related]
16. Troglitazone decreases serum uric acid concentrations in type II diabetic patients and non-diabetics.
Iwatani M; Wasada T; Katsumori K; Watanabe-Takahashi C; Kamatani N; Iwamoto Y
Diabetologia; 2000 Jun; 43(6):814-5. PubMed ID: 10907128
[No Abstract] [Full Text] [Related]
17. Troglitazone reduces hyperglycaemia and selectively acute-phase serum proteins in patients with Type II diabetes.
Ebeling P; Teppo AM; Koistinen HA; Viikari J; Rönnemaa T; Nissén M; Bergkulla S; Salmela P; Saltevo J; Koivisto VA
Diabetologia; 1999 Dec; 42(12):1433-8. PubMed ID: 10651262
[TBL] [Abstract][Full Text] [Related]
18. The effect of insulin sensitizer, troglitazone, on lipoprotein lipase mass in preheparin serum.
Shirai K; Itoh Y; Sasaki H; Totsuka M; Murano T; Watanabe H; Miyashita Y
Diabetes Res Clin Pract; 1999 Oct; 46(1):35-41. PubMed ID: 10580614
[TBL] [Abstract][Full Text] [Related]
19. [Troglitazone].
Yamanouchi T
Nihon Rinsho; 2000 Feb; 58(2):389-94. PubMed ID: 10707563
[TBL] [Abstract][Full Text] [Related]
20. Switching insulin-sensitizing agents in patients with type 2 diabetes who require insulin.
Blonde L; Sandberg MI; Guthrie RD
Diabetes Care; 1999 Jun; 22(6):1004-6. PubMed ID: 10372262
[No Abstract] [Full Text] [Related]
[Next] [New Search]
